fc 777 casino login philippines download no deposit bonus As part of a national “moonshot” to cure blindness, researchers at the CU Anschutz Medical Campus will receive as much as $46 million in federal funding over the next five years to pursue a first-of-its-kind full eye transplantation. “This is no easy undertaking, but I believe we can achieve this together,” said Dr. Kia Washington, the lead researcher for the University of Colorado-led team, during a press conference Monday. “And in fact I’ve never been more hopeful that a cure for blindness is within reach.” The CU team was one of four in the United States that received funding awards from the federal Advanced Research Projects Agency for Health , or ARPA-H. The CU-based group will focus on achieving the first-ever vision-restoring eye transplant by using “novel stem cell and bioelectronic technologies,” according to a news release announcing the funding. The work will be interdisciplinary, Washington and others said, and will link together researchers at institutions across the country. The four teams that received the funding will work alongside each other on distinct approaches, though officials said the teams would likely collaborate and eventually may merge depending on which research avenues show the most promise toward achieving the ultimate goal of transplanting an eye and curing blindness. Dr. Calvin Roberts, who will oversee the broader project for ARPA-H, said the agency wanted to take multiple “shots on goal” to ensure progress. “In the broader picture, achieving this would be probably the most monumental task in medicine within the last several decades,” said Dr. Daniel Pelaez of the University of Miami’s Bascom Palmer Eye Institute, which also received ARPA-H funding. Pelaez is the lead investigator for that team, which has pursued new procedures to successfully remove and preserve eyes from donors, amid other research. He told The Denver Post that only four organ systems have not been successfully transplanted: the inner ear, the brain, the spinal cord and the eye. All four are part of the central nervous system, which does not repair itself when damaged. If researchers can successfully transplant the human eye and restore vision to the patient, it might help unlock deeper discoveries about repairing damage to the brain and spine, Pelaez said, as well as addressing hearing loss. To succeed, researchers must successfully remove and preserve eyes from donors and then successfully connect and repair the optical nerve, which takes information from the eye and tells the brain what the eye sees. A team at New York University performed a full eye transplant on a human patient in November 2023, though the procedure — while a “remarkable achievement,” Pelaez said — did not restore the patient’s vision. It was also part of a partial face transplant; other approaches pursued via the ARPA-H funding will involve eye-specific transplants. Washington, the lead CU researcher, said she and her colleagues have already completed the eye transplant procedure — albeit without vision restoration — in rats. The CU team will next work on large animals to advance “optic nerve regenerative strategies,” the school said, as well as to study immunosuppression, which is critical to ensuring that patients’ immune systems don’t reject a donated organ. The goal is to eventually advance to human trials. Pelaez and his colleagues have completed their eye-removal procedure in cadavers, he said, and they’ve also studied regeneration in several animals that are capable of regenerating parts of their eyes, like salamanders or zebra fish. His team’s funding will focus in part on a life-support machine for the eye to keep it healthy and viable during the removal process. InGel Therapeutics, a Massachusetts-based Harvard spinoff and the lead of a third team, will pursue research on 3-D printed technology and “micro-tunneled scaffolds” that carry certain types of stem cells as part of a focus on optical nerve regeneration and repair, ARPA-H said. ARPH-A, created two years ago, will oversee the teams’ work. Researchers at 52 institutions nationwide will also contribute to the teams. The CU-led group will include researchers from the University of Southern California, the University of Wisconsin, Indiana University and Johns Hopkins University, as well as from the National Eye Institute . The teams will simultaneously compete and collaborate: Pelaez said his team has communicated with researchers at CU and at Stanford, another award recipient, about their eye-removal research. The total funding available for the teams is $125 million, ARPA-H officials said Monday, and it will be distributed in phases, in part dependent on teams’ success. U.S. Rep. Diana DeGette, a Democrat who represents Denver in Congress, acknowledged the recent election results at the press conference Monday and pledged to continue fighting to preserve ARPA-H’s funding under President-elect Donald Trump’s administration. The effort to cure blindness, Washington joked, was “biblical” in its enormity — a reference to the Bible story in which Jesus cures a blind man. She and others also likened it to a moonshot, meaning the effort to successfully put Neil Armstrong and Buzz Aldrin on the moon nearly 50 years ago. If curing blindness is similar to landing on the moon, then the space shuttle has already left the launchpad, Washington said. “We have launched,” she said, “and we are on our trajectory.”Chesapeake Utilities Corporation Announces $100 Million At-The-Market Equity Offering Program

HONG KONG , Dec. 3, 2024 /PRNewswire/ -- Dunxin Financial Holdings Limited ("Dunxin" or the "Company") (OTC Pink: DXFFY), a company engaged in real estate operation management and investment and a digital technology security business in Hong Kong , today announced that it plans to change the ratio of its American depositary shares ("ADSs") from one (1) ADS representing four hundred and eighty (480) Class A ordinary shares to one (1) ADS representing sixty thousand (60,000) Class A ordinary shares. The effect of the ratio change on the ADS trading price on the OTC Pink (the "OTC") is expected to take place at the open of trading on December 4, 2024 (U.S. Eastern Time). For the Company's ADS holders, the ADS ratio change will have the same effect as a one-for-one hundred and twenty-five reverse split. There will be no change to the Company's Class A ordinary shares. ADS holders of record on the effective date will need to surrender their ADS to the depositary bank for cancellation and exchange in connection with the ADS ratio change, with further details to be provided in the notice by the depositary bank. As of the effective date for the ADS ratio change, Dunxin's ADSs will continue to be traded on the OTC under the symbol "DXFFY". No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than the ADS price on a proportionate basis. About Dunxin Financial Holdings Limited Dunxin is a licensed microfinance lender serving individuals and SMEs in Hubei Province , China . Dunxin suspended offering loans to its customers since 2020. Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.As part of a national “moonshot” to cure blindness, researchers at the CU Anschutz Medical Campus will receive as much as $46 million in federal funding over the next five years to pursue a first-of-its-kind full eye transplantation. “This is no easy undertaking, but I believe we can achieve this together,” said Dr. Kia Washington, the lead researcher for the University of Colorado-led team, during a press conference Monday. “And in fact I’ve never been more hopeful that a cure for blindness is within reach.” The CU team was one of four in the United States that received funding awards from the federal Advanced Research Projects Agency for Health , or ARPA-H. The CU-based group will focus on achieving the first-ever vision-restoring eye transplant by using “novel stem cell and bioelectronic technologies,” according to a news release announcing the funding. The work will be interdisciplinary, Washington and others said, and will link together researchers at institutions across the country. The four teams that received the funding will work alongside each other on distinct approaches, though officials said the teams would likely collaborate and eventually may merge depending on which research avenues show the most promise toward achieving the ultimate goal of transplanting an eye and curing blindness. Dr. Calvin Roberts, who will oversee the broader project for ARPA-H, said the agency wanted to take multiple “shots on goal” to ensure progress. “In the broader picture, achieving this would be probably the most monumental task in medicine within the last several decades,” said Dr. Daniel Pelaez of the University of Miami’s Bascom Palmer Eye Institute, which also received ARPA-H funding. Pelaez is the lead investigator for that team, which has pursued new procedures to successfully remove and preserve eyes from donors, amid other research. He told The Denver Post that only four organ systems have not been successfully transplanted: the inner ear, the brain, the spinal cord and the eye. All four are part of the central nervous system, which does not repair itself when damaged. If researchers can successfully transplant the human eye and restore vision to the patient, it might help unlock deeper discoveries about repairing damage to the brain and spine, Pelaez said, as well as addressing hearing loss. To succeed, researchers must successfully remove and preserve eyes from donors and then successfully connect and repair the optical nerve, which takes information from the eye and tells the brain what the eye sees. A team at New York University performed a full eye transplant on a human patient in November 2023, though the procedure — while a “remarkable achievement,” Pelaez said — did not restore the patient’s vision. It was also part of a partial face transplant; other approaches pursued via the ARPA-H funding will involve eye-specific transplants. Washington, the lead CU researcher, said she and her colleagues have already completed the eye transplant procedure — albeit without vision restoration — in rats. The CU team will next work on large animals to advance “optic nerve regenerative strategies,” the school said, as well as to study immunosuppression, which is critical to ensuring that patients’ immune systems don’t reject a donated organ. The goal is to eventually advance to human trials. Pelaez and his colleagues have completed their eye-removal procedure in cadavers, he said, and they’ve also studied regeneration in several animals that are capable of regenerating parts of their eyes, like salamanders or zebra fish. His team’s funding will focus in part on a life-support machine for the eye to keep it healthy and viable during the removal process. InGel Therapeutics, a Massachusetts-based Harvard spinoff and the lead of a third team, will pursue research on 3-D printed technology and “micro-tunneled scaffolds” that carry certain types of stem cells as part of a focus on optical nerve regeneration and repair, ARPA-H said. ARPH-A, created two years ago, will oversee the teams’ work. Researchers at 52 institutions nationwide will also contribute to the teams. The CU-led group will include researchers from the University of Southern California, the University of Wisconsin, Indiana University and Johns Hopkins University, as well as from the National Eye Institute . The teams will simultaneously compete and collaborate: Pelaez said his team has communicated with researchers at CU and at Stanford, another award recipient, about their eye-removal research. The total funding available for the teams is $125 million, ARPA-H officials said Monday, and it will be distributed in phases, in part dependent on teams’ success. U.S. Rep. Diana DeGette, a Democrat who represents Denver in Congress, acknowledged the recent election results at the press conference Monday and pledged to continue fighting to preserve ARPA-H’s funding under President-elect Donald Trump’s administration. The effort to cure blindness, Washington joked, was “biblical” in its enormity — a reference to the Bible story in which Jesus cures a blind man. She and others also likened it to a moonshot, meaning the effort to successfully put Neil Armstrong and Buzz Aldrin on the moon nearly 50 years ago. If curing blindness is similar to landing on the moon, then the space shuttle has already left the launchpad, Washington said. “We have launched,” she said, “and we are on our trajectory.”

OTTAWA — NDP Leader Jagmeet Singh said he won't play Conservative Leader Pierre Poilievre's games by voting to bring down the government on an upcoming non-confidence motion. The Conservatives plan to introduce a motion that quotes Singh's own criticism of the Liberals, and asks the House of Commons to declare that it agrees with Singh and has no confidence in the government. The motion is expected to be introduced on Thursday and the debate and vote are set for Monday. Singh said he is not going to trigger an election when he believes Poilievre would cut programs the NDP fought for. "I'm not going to be playing Pierre Poilievre's games. I have no interest in that. We're frankly not going to allow him to cut the things that people need. I want to actually have dental care expanded, I want people to actually start to benefit from the pharmacare legislation we passed," Singh said. With the NDP's expected support, the Liberals should survive this next confidence vote brought forward by the Conservatives. The Tories have vowed to bring forward non-confidence motions every chance they get. The party will have two more opposition motions after this one, which are expected to continue to call for non-confidence. The NDP are scheduled to have their opposition day on Friday. Earlier on Tuesday, Singh did acknowledge that the Conservatives have a sizeable lead on the NDP in public opinion polls, while giving a campaign-style speech to visiting party staffers from across the country. Most pollsters in Canada have recorded a roughly 20 point lead for the Conservatives over both the Liberals and NDP for the last few months. The non-confidence vote was scheduled after Speaker Greg Fergus intervened to pause a filibuster on a privilege debate about a green technology fund. The Conservatives have said they would only end that debate if the NDP agree to topple the government or if the Liberals turn over unredacted documents at the centre of the parliamentary gridlock. This report by The Canadian Press was first published Dec. 3, 2024. David Baxter, The Canadian Press

Adam Clark scores 18 to help Merrimack knock off Niagara 80-62Toll Road Funds Mulled for Tijuana River ValleyCover Five: What to make of wild week around Nebraska football, and 5 biggest impact signees

ST. PETERSBURG, Fla., Dec. 03, 2024 (GLOBE NEWSWIRE) -- On December 3, 2024, the Raymond James Financial, Inc. RJF Board of Directors declared a quarterly cash dividend on shares of its common stock of $0.50 per share, payable January 16, 2025 to shareholders of record on January 2, 2025. This is an 11.1% increase over the previous dividend of $0.45 per share paid on October 15, 2024. The Board declared a quarterly dividend of $0.3984375 per depositary share of 6.375% Fixed-to-Floating Rate Series B Non-Cumulative Perpetual Preferred Stock (NYSE: RJF PrB) payable January 2, 2025, to shareholders of record on December 16, 2024. The Board also authorized repurchase of the company's shares of common stock in an aggregate amount of up to $1.5 billion. The $1.5 billion authorization replaces the previous repurchase authorization of $1.5 billion announced on November 30, 2023, under which approximately $644 million was remaining as of December 3, 2024. The repurchases may be made from time to time at prices that the company deems appropriate and subject to market conditions, applicable law, regulatory constraints in connection with previously announced acquisitions and other factors. Such repurchases may be made in the open market, in privately negotiated transactions, or otherwise. The Board's authorization does not have a fixed expiration date. The repurchase authorization does not obligate the company to repurchase any dollar amount or number of securities and may be suspended or discontinued at any time. About Raymond James Financial, Inc. Raymond James Financial, Inc. RJF is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. The company has approximately 8,800 financial advisors. Total client assets are $1.54 trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com . Forward-Looking Statements Certain statements made in this press release may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning future shareholder distributions. Forward-looking statements are not guarantees, and they involve risks, uncertainties and assumptions. Although we make such statements based on assumptions that we believe to be reasonable, there can be no assurance that actual results will not differ materially from those expressed in the forward-looking statements. We caution investors not to rely unduly on any forward-looking statements and urge you to carefully consider the risks described in our filings with the Securities and Exchange Commission (the "SEC") from time to time, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are available at www.raymondjames.com and the SEC's website at www.sec.gov . We expressly disclaim any obligation to update any forward-looking statement in the event it later turns out to be inaccurate, whether as a result of new information, future events, or otherwise. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Sources close to Donald Trump Jr. and fiancée Kimberly Guilfoyle confirm they have split days after his President-elect father nominated Guilfoyle to serve as ambassador to Greece and on the heels Jr. getting cozy with a Florida socialite. The Trumps remain “enamored” with the 55-year-old former Fox News host, the ex-wife of California Gov. Gavin Newsom and businessman Eric Villency, an insider told People. “It’s a friendly split,” the source said of the exes’ ”very long engagement.” The pair got engaged in 2020 but didn’t make the news public until early 2022. Though the source praised the former prosecutor as “very intelligent, very smart, very loyal,” they said Guilfoyle is “very direct, very matter of fact” and, as a result, “not easy to deal with.” The insider added that Guilfoyle remains on good terms with her would-be father-in-law, as she knew the President-elect before she knew his son. “Even before she and Don were together, she was close with the family,” said the insider. “She knew Donald before she knew Don Jr., and that connection is strong. So nothing has changed.” Don Jr., 46, has recently been seen holding hands with Bettina Anderson, who the source says “would impress” Trump senior. “Don Jr. has always wanted to look good in his father’s eyes,” said the insider. “Someone like Bettina, who is and has been a model, and is in Waspy circles of Palm Beach is something that would impress him.” People reported earlier this week that the pair’s been seeing one another for “about six months,” while Don Jr. “was still very much with Kim.” The source who shared that said the dad of five “introduced [Anderson] around as his girlfriend” during that time. Pelosi has remained a major political force in the Democratic Party even after handing the Democratic baton in the House to Brooklyn Rep. Hakeem Jeffries, who recently won a second two-year term as minority leader. She was credited with bulldozing President Biden into dropping his reelection bid after a dismal performance in a debate with President-elect Trump. The two Democratic allies admit they haven’t spoken since, a sign of continuing friction. — New York Daily News

The Better Business Bureau of Mainland B.C. is urging people to be vigilant to avoid scammers during the postal strike. Since Nov. 15, around 55,000 members of the Canadian Union of Postal Workers have been on strike. During this time, some fake package delivery scams have been circulating. The Better Business Bureau offers tips for people to protect themselves from scammers as the strike continues. Avoid unsolicited offers from individuals or companies claiming they can deliver your mail or packages during the strike. Research reviews and check for a BBB Accreditation before choosing a service. Scammers may send fake messages claiming to be from Canada Post or alternative couriers, requesting payment for undelivered items or offering priority service. Do not click on links in unsolicited emails or texts. Instead, visit the official website of the courier service for updates. Be cautious of ads or posts on social media offering mail delivery services. Many fraudulent businesses advertise on platforms with the intention of stealing personal information or money. Use the official tracking tool provided by the seller or courier. Fraudulent companies may provide fake tracking numbers to appear legitimate. These include urgent requests for payment or sensitive information. Other warning signs include poor grammar, unprofessional logos or contact information that does not match official sources. Anyone who suspects a scam is urged to report it to the BBB Scam Tracker to help protect others. The scam tracker is online at .Chesapeake Utilities Corporation Announces $100 Million At-The-Market Equity Offering Program